The global tumor genomics market is expected to reach a market size of 56.54 Billion by 2028 and register a double-digit CAGR over the forecast period, according to latest analysis by Emergen Research. The steady projected growth can be attributed to technological innovations in the field of genomics. Mergers and acquisitions between key players in the field is another key factor driving market growth. Increasing research on cancer, usage of genomic systems among academics and government institutions, and decreasing cost of sequencing is contributing significantly to growth in cancer diagnostics. Moreover, advances in computational approaches in tumor genomics has resulted in shorter result time, which is a key factor driving adoption, and thus driving growth of the market. Tumor is often caused by genetic alterations, including gene fusions, large chromosomal rearrangements; however, next generation sequencing techniques have helped researchers gather vast amounts of tumor genomic data and record genetic mutations in various cancer types.
Get a sample of the report : https://www.emergenresearch.com/request-sample/531
In September 2018, Cancer Genetics Inc. and NovellusDx Ltd. signed a merger agreement in order to combine their data associated to tumor anatomy. The aim behind the merger is to enhance and accelerate the therapeutic development to improve treatment success rates for companies. With the proprietary technology and machine learning technology of NovellusDX Ltd., Cancer Genetics aims to form a leading oncology-focused precision medicine company.
Biomarkers play an important role in the detection of cancer and it may be used to detect early cancer symptoms or to perform differential diagnosis of cancerous tumors.
Key players in genomic biomarkers are Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Pacific Biosciences of California, Inc., NeoGenomics Laboratories, Inc., Myriad Genetics, Inc., and PerkinElmer.
Market Scope:
One of the report’s central components is the broad Tumor Genomics market segmentation that includes the product type gamut, application spectrum, end-user industry landscape, significant geographical regions, and the top market contenders. The key players’ financial positions, along with their gross profits, sales volumes, sales revenue, manufacturing costs, and other financial ratios, have been accurately gauged in the report. Furthermore, several analytical tools like investment assessment, SWOT analysis, and Porter’s Five Forces Analysis have been implemented by our analysts’ team to evaluate the production and distribution capacities of the Tumor Genomics market players.
Emergen Research has segmented the global tumor genomic market on the basis of technique, application, end-use, and region:
Technique Outlook (Revenue, USD Billion; 2021–2028)
- Next Generation Sequencing Technique (NGS)
- Polymerase Chain Reaction (PCR)
- Microarray
- In-Situ Hybridization (ISH)
- Immunohistochemistry (ICH)
- Others (Mass Spectrometry and Flow Cytometry)
Request a discount on the report : https://www.emergenresearch.com/request-discount/531
Application Outlook (Revenue, USD Billion; 2021–2028)
- Diagnostics and Monitoring
- Drug Discovery and Development
- Biomarker Discovery
End-use Outlook (Revenue, USD Billion; 2021–2028)
- Academics and Research Organizations
- Hospitals and Ambulatory Clinics
- Clinical and Diagnostic Laboratories
- Biotechnology and Pharmaceutical Company
TOC of the global Tumor Genomics market report:
Chapter 1, describes the Tumor Genomics Introduction, market overview, product offerings, growth opportunities, market risks, driving forces, and challenges.
Chapter 2, analyzes the key manufacturers of Tumor Genomics , along with the sales, revenue, and price of Tumor Genomics , in the forecast period.
Chapter 3, studies the competitive situation among the major manufacturers and vendors, with sales, revenue, and market share.
Chapter 4, analyzes the global market by regions, with sales, revenue, and market share of Tumor Genomics , for each region, from 2020 to 2027.
Chapters 5, 6, 7, 8 and 9, analyze the Tumor Genomics market by type, application, regions, and manufacturers, with sales, revenue, and market share by key countries in these regions…Continued
Key Points of Tumor Genomics Market:
Extensive coverage of the analysis of the Tumor Genomics market
Key insights into the regional spread of the industry in key geographies
Radical insights into the vital market trends; both current and emerging trends, and factors influencing the growth of the market
Comprehensive coverage of the impact of the COVID-19 pandemic on the overall growth of the Tumor Genomics market
Complete data about the key manufacturers and vendors in the Tumor Genomics market
Read More: https://www.emergenresearch.com/industry-report/tumor-genomics-market
Related reports:
Patient Engagement Solutions Market: https://www.emergenresearch.com/industry-report/patient-engagement-solutions-market
Nucleic Acid Isolation and Purification Market: https://www.emergenresearch.com/industry-report/nucleic-acid-isolation-and-purification-market
Non-Invasive Prenatal Testing Market: https://www.emergenresearch.com/industry-report/non-invasive-prenatal-testing-market
RNA Transcriptomics Market: https://www.emergenresearch.com/industry-report/in-vitro-fertilization-market
Blockchain in Healthcare: Https://www.forbes.com/sites/forbestechcouncil/2021/12/07/four-key-medtech-software-development-trends-for-2022/?sh=23e843f420d5
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs
